SARcode Bioscience

SARcode Corporation is a private San Francisco based biopharmaceutical company engaged in the development of a novel class of small molecule lymphocyte function-associated antigen-1 (LFA-1; CD11a/CD18; αLβ2) antagonists as a topical agent for the...

Founded in 2006
Total money raised: $73M

94005 1000 Marina Blvd.
Suite 250

Updated on Sep 1, 2013
SARcode Bioscience at CrunchBase
Flemming Ornskov Chief Executive Officer
Graham Hetherington Chief Financial Officer
Matthew W. Emmens Board Member
Anne Minto Board of Directors
Dennis Henner Board of Directors
Tatjana May General Counsel
David Kappler Board of Directors
Susan Kilsby Board of Directors
Quinton Oswald CEO

March, 2013

SARcode Bioscience was acquired by Shire
for $160M

Shire to Acquire Dry-Eye Drug Developer SARcode Bioscience

July, 2011

SARcode Bioscience raised $44M in a Series B round from Sofinnova Ventures, Rho Capital Partners, Alta Partners, and Clarus Ventures

SARcode Bioscience Closes $44M Series B Financing

December, 2006

SARcode Bioscience raised $29M in unattributed round from Alta Partners and Clarus Ventures

SARcode secured $25 million in financing


SARcode Bioscience was founded in 2006